NO20015329L - Pyrimidinon-forbindelser - Google Patents

Pyrimidinon-forbindelser

Info

Publication number
NO20015329L
NO20015329L NO20015329A NO20015329A NO20015329L NO 20015329 L NO20015329 L NO 20015329L NO 20015329 A NO20015329 A NO 20015329A NO 20015329 A NO20015329 A NO 20015329A NO 20015329 L NO20015329 L NO 20015329L
Authority
NO
Norway
Prior art keywords
pyrimidinone compounds
pyrimidinone
compounds
Prior art date
Application number
NO20015329A
Other languages
English (en)
Other versions
NO20015329D0 (no
Inventor
Ashley Edward Fenwick
Deirdre Mary Bernadette Hickey
Robert John Ife
Colin Andrew Leach
Ivan Leo Pinto
Stephen Allan Smith
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9910048A external-priority patent/GB9910048D0/en
Priority claimed from GB0002096A external-priority patent/GB0002096D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of NO20015329D0 publication Critical patent/NO20015329D0/no
Publication of NO20015329L publication Critical patent/NO20015329L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20015329A 1999-05-01 2001-10-31 Pyrimidinon-forbindelser NO20015329L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9910048A GB9910048D0 (en) 1999-05-01 1999-05-01 Novel compounds
GB0002096A GB0002096D0 (en) 2000-01-28 2000-01-28 Novel compounds
PCT/EP2000/003727 WO2000066567A1 (en) 1999-05-01 2000-04-25 Pyrimidinone compounds

Publications (2)

Publication Number Publication Date
NO20015329D0 NO20015329D0 (no) 2001-10-31
NO20015329L true NO20015329L (no) 2001-10-31

Family

ID=26243514

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20015329A NO20015329L (no) 1999-05-01 2001-10-31 Pyrimidinon-forbindelser

Country Status (29)

Country Link
US (2) US6953803B1 (no)
EP (2) EP1479671B1 (no)
JP (1) JP2002543190A (no)
KR (1) KR20020012200A (no)
CN (1) CN1286822C (no)
AR (1) AR023777A1 (no)
AT (2) ATE283845T1 (no)
AU (1) AU766003B2 (no)
BR (1) BR0010220A (no)
CA (1) CA2371671A1 (no)
CO (1) CO5170521A1 (no)
CZ (1) CZ20013904A3 (no)
DE (2) DE60016397T2 (no)
DK (1) DK1175408T3 (no)
ES (1) ES2233361T3 (no)
HK (1) HK1044757B (no)
HU (1) HUP0201122A3 (no)
IL (1) IL146210A0 (no)
MX (1) MXPA01011186A (no)
MY (1) MY136037A (no)
NO (1) NO20015329L (no)
NZ (1) NZ515137A (no)
PE (1) PE20010070A1 (no)
PL (1) PL351690A1 (no)
PT (1) PT1175408E (no)
SI (1) SI1175408T1 (no)
TR (1) TR200103216T2 (no)
UY (1) UY26132A1 (no)
WO (1) WO2000066567A1 (no)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL146210A0 (en) * 1999-05-01 2002-07-25 Smithkline Beecham Plc Pyrimidinone compounds
DE60121550T2 (de) 2000-02-16 2007-06-21 Smithkline Beecham Plc, Brentford Pyrimidin-4-onderivat als LDL-PLA2 Inhibitor
GB0024808D0 (en) 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
GB0119793D0 (en) * 2001-08-14 2001-10-03 Smithkline Beecham Plc Novel compounds
GB0127143D0 (en) * 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0127139D0 (en) * 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0208280D0 (en) * 2002-04-10 2002-05-22 Glaxo Group Ltd Novel compounds
EP1644353A1 (de) * 2003-07-02 2006-04-12 Bayer HealthCare AG Amid-substituierte 1, 2, 4-triazin-5 (2h) - one zur behandlung von chronisch inflammatorischen krankheiten
US20150017671A1 (en) 2004-04-16 2015-01-15 Yaping Shou Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
US7741020B2 (en) 2004-04-16 2010-06-22 Glaxo Group Limited Methods for detecting Lp-PLA2 activity and inhibition of Lp-PLA2 activity
DE102004061006A1 (de) * 2004-12-18 2006-06-22 Bayer Healthcare Ag 3-Benzylthio-1,2,4-triazin-5(2H)-one
DE102004061009A1 (de) * 2004-12-18 2006-06-22 Bayer Healthcare Ag Substituierte 1,2,4-Triazin-5(2H)-one
CN1954826A (zh) * 2005-10-26 2007-05-02 上海生物芯片有限公司 银杏叶提取物在降低胆固醇方面的用途
EA018101B1 (ru) 2007-05-11 2013-05-30 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Способы лечения кожных язв
WO2008140449A1 (en) 2007-05-11 2008-11-20 Thomas Jefferson University Methods of treatment and prevention of neurodegenerative diseases and disorders
AR081399A1 (es) 2010-05-17 2012-08-29 Glaxo Group Ltd Proceso para preparar un compuesto de pirimidinona, compuestos intermediarios en dicho proceso y procesos para repararlos.
US8637536B2 (en) 2010-12-06 2014-01-28 Glaxo Group Limited Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2
CN104478812A (zh) * 2010-12-06 2015-04-01 葛兰素集团有限公司 用于治疗由Lp-PLA2介导的疾病或病症的嘧啶酮化合物
ES2847883T3 (es) 2010-12-17 2021-08-04 Glaxo Group Ltd Uso de inhibidores de LP-PLA2 en el tratamiento y prevención de enfermedades oculares
WO2013000108A1 (zh) * 2011-06-27 2013-01-03 中国科学院上海药物研究所 唑类杂环化合物、其制备方法、药物组合物和用途
AR087309A1 (es) 2011-07-27 2014-03-12 Glaxo Group Ltd Compuesto heterociclico de anillos condensados sustituido, composicion farmaceutica que lo comprende y su uso para la fabricacion de un medicamento para el tratamiento de enfermedades neurogenerativas y aterosclerosis
US8975400B2 (en) 2011-07-27 2015-03-10 Glaxo Group Limited 2,3-dihydroimidazo[1, 2-c] pyrimidin-5(1 H)-one compounds use as LP-PLA2 inhibitors
EA027324B1 (ru) * 2011-11-11 2017-07-31 Пфайзер Инк. 2-тиопиримидиноны
EP2948457A4 (en) 2013-01-25 2016-09-07 Glaxosmithkline Ip Dev Ltd COMPOUNDS
UY35276A (es) 2013-01-25 2014-08-29 Glaxosmithkline Ip Dev Ltd Nuevos compuestos que inhiben la actividad de Lp-PLA2
CA2899143A1 (en) 2013-01-25 2014-07-31 Glaxosmithkline Intellectual Property Development Limited Bicyclic pyrimidone compounds as inhibitors of lp-pla2
US20140283157A1 (en) 2013-03-15 2014-09-18 Diadexus, Inc. Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
US9552473B2 (en) 2014-05-14 2017-01-24 Microsoft Technology Licensing, Llc Claiming data from a virtual whiteboard
WO2016012916A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
WO2016012917A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
CN104840963B (zh) * 2015-05-26 2018-02-16 河北东康生物科技有限公司 含脂蛋白相关性磷脂酶a2抑制剂的药物组合物及应用
CN106008362B (zh) * 2016-05-24 2018-08-10 杰达维（上海）医药科技发展有限公司 一种嘧啶衍生物的制备方法
JP6545747B2 (ja) * 2017-05-09 2019-07-17 山田化学工業株式会社 色素化合物
US20230044787A1 (en) 2019-11-09 2023-02-09 Shanghai SIMR Biotechnology Co., Ltd Tricycle dihydroimidazopyrimidone derivative, preparation method thereof, pharmaceutical composition and use thereof
CN115304620A (zh) 2021-05-07 2022-11-08 上海赛默罗生物科技有限公司 嘧啶酮衍生物、其制备方法、药物组合物和用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1582527A (en) * 1975-12-29 1981-01-07 Smith Kline French Lab Pyrimidone and thiopyrimidone derivatives
ES2203988T3 (es) 1997-11-06 2004-04-16 Smithkline Beecham Plc Compuestos de pirimidinona y composiciones farmaceuticas que los contienen.
WO2000010980A1 (en) 1998-08-21 2000-03-02 Smithkline Beecham Plc Pyrimidinone derivatives for the treatment of atherosclerosis
IL146210A0 (en) * 1999-05-01 2002-07-25 Smithkline Beecham Plc Pyrimidinone compounds

Also Published As

Publication number Publication date
DE60042286D1 (de) 2009-07-09
CO5170521A1 (es) 2002-06-27
KR20020012200A (ko) 2002-02-15
US6953803B1 (en) 2005-10-11
PT1175408E (pt) 2005-04-29
HUP0201122A3 (en) 2003-11-28
DK1175408T3 (da) 2005-04-11
NO20015329D0 (no) 2001-10-31
NZ515137A (en) 2003-10-31
US7115616B2 (en) 2006-10-03
HK1044757B (zh) 2005-07-08
EP1479671A1 (en) 2004-11-24
CN1286822C (zh) 2006-11-29
MY136037A (en) 2008-08-29
HK1044757A1 (en) 2002-11-01
EP1479671B1 (en) 2009-05-27
DE60016397T2 (de) 2005-12-01
CZ20013904A3 (cs) 2002-04-17
ATE283845T1 (de) 2004-12-15
TR200103216T2 (tr) 2002-04-22
HUP0201122A2 (en) 2002-08-28
AR023777A1 (es) 2002-09-04
CA2371671A1 (en) 2000-11-09
MXPA01011186A (es) 2002-08-12
JP2002543190A (ja) 2002-12-17
UY26132A1 (es) 2000-12-29
EP1175408A1 (en) 2002-01-30
AU766003B2 (en) 2003-10-09
DE60016397D1 (de) 2005-01-05
EP1175408B1 (en) 2004-12-01
BR0010220A (pt) 2002-05-14
PE20010070A1 (es) 2001-03-10
US20040167142A1 (en) 2004-08-26
WO2000066567A1 (en) 2000-11-09
SI1175408T1 (en) 2005-04-30
ES2233361T3 (es) 2005-06-16
IL146210A0 (en) 2002-07-25
ATE432265T1 (de) 2009-06-15
AU4120300A (en) 2000-11-17
CN1358175A (zh) 2002-07-10
PL351690A1 (en) 2003-06-02

Similar Documents

Publication Publication Date Title
DK1175408T3 (da) Pyrimidinonforbindelser
CY2015035I1 (el) Ενωσεις πυριμιδινης
EE200100502A (et) Ühendid
NO20024127D0 (no) Pyrimidin-forbindelser
NO20016115D0 (no) Substituerte heterocykelkondenserte gamma-karboliner
PT1224180E (pt) Azois substituidos
IS6239A (is) Ný efnasambönd
EE200200224A (et) Uudsed ühendid
IS6139A (is) Ný efnasambönd
ID29533A (id) Senyawa-senyawa kalsilitik
NO20021503D0 (no) Kinazolinoner
NO20020466L (no) Kalsilytiske forbindelser
IS6141A (is) Ný efnasambönd
NO20014262D0 (no) Tiazoloindolinon-forbindelser
NO20022927D0 (no) Substituerte pyrrazoler
NO20021502D0 (no) Kinazolinoner
DE50003921D1 (de) Substituierte phenyluracile
ID29984A (id) Senyawa-senyawa bis-stirilbifenil
SE9901271D0 (sv) Novel compounds
SE9901118D0 (sv) Novel compounds
SE9901117D0 (sv) Novel compounds
SE9903838D0 (sv) Novel compounds
SE9904651D0 (sv) Novel compounds
SE9901270D0 (sv) Novel compounds
SE9902764D0 (sv) Novel compounds

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application